// App-Quantinova.ai

SAT0550 (2018) : Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial

Researchers

Presenter

  • V. Strand

Principal Investigators

  • S. Dimonaco

  • K. Tuckwell

  • M. Klearman

  • N. Collinson

  • J.H. Stone

Medical Centers

  • Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA

  • Roche Products Limited, Welwyn Garden City

  • Genentech, South Sanfrancisco, CA.

  • Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Cardiovascular (CVS)

Disease

  • Giant cell arteritis

Biomarkers

  • N/A

Drug/Treatment

  • Tocilizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Roche Holding AG

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved